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ABSTRACT 
DANA DAUGHERTY: Opioid Antinociception and Antihyperalgesia in 
Combination with Metabotropic Glutamate Receptor Antagonism 
(Under the direction of Linda Dykstra, Ph.D.) 
 
Research has shown that the analgesic effects of mu-opioids can be 
enhanced by concurrent administration of drugs that target various sites within 
the glutamate system.  To explore these effects, the present study examined the 
effects of a metabotropic glutamate receptor subtype 1 (mGluR1) antagonist and 
a metabotropic glutamate receptor subtype 5 (mGluR5) antagonist in 
combination with morphine.  These interactions were examined in two models of 
acute pain and one model of inflammatory pain.  Selected doses of the mGluR1 
antagonist JNJ16259685 (1.0 – 5.6 mg/kg) and the mGluR5 antagonist MPEP 
(30.0 mg/kg) enhanced morphine antinociception in both models of acute pain.  
Neither antagonist enhanced morphine-antihyperalgesia in the model of 
inflammatory pain; however, MPEP (10.0 mg/kg) did attenuate the 
antihyperalgesic effects of high doses of morphine.  These results suggest that 
the interaction between the mGluR and opioid receptor systems depends on the 
assay used to examine these effects and the dose combinations examined.
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CHAPTER 1 
INTRODUCTION 
 
Literature Review 
Pharmacological agonists of the endogenous opiate system produce both 
reliable analgesia and an array of side effects.  The most relevant clinical opioid 
compound, morphine, binds to and activates the family of mu (µ)-opiate receptors 
(MORs) with high affinity (Nishimura et al., 1984).  Endogenous activation of the 
MOR by opiates such as endorphins and enkephalins results in mild analgesia 
(Belluzi et al., 1976; Hughes et al., 1975).  Morphine mimics this activation but 
with higher efficacy (Pasternak, 1981), which has made it a standard in clinical 
pain management; however, morphine’s analgesic use is often limited by a 
number of undesirable side effects. 
The side effects of morphine and other µ-opioid agonists can include, 
among others, respiratory depression, decreased blood pressure and heart rate, 
nausea, and constipation (Caligano et al., 1991; Trescot et al., 2008).  In addition 
to these effects, repeated use of morphine carries additional risks.  For example, 
physical dependence is a common complication of repeated opioid exposure.  In 
addition to physical dependence, repeated exposure to morphine and other µ-
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opioids can result in tolerance (Koch & Hollt, 2008), in which a higher dose of the 
drug is needed to achieve the same effect previously produced by a lower dose.  
Tolerance to the analgesic effects of morphine and other µ-opioid agonist 
compounds is a great concern for many clinicians and preclinical researchers.  
While increasing the morphine dose in a tolerant individual will produce sufficient 
analgesia, the increase in dose may increase the occurrence of morphine’s other 
effects, such as respiratory depression.  Even in response to acute dosing, it can 
be difficult to balance morphine’s analgesic efficacy with its side effect profile.  
For this reason, many preclinical researchers have turned their efforts to 
enhancing the analgesic effects of morphine and other opioid compounds without 
also increasing the many side effects of this pharmacological class. 
The excitatory amino acid glutamate plays a facilitatory role in pain 
processing.  Glutamatergic inputs from afferent nociceptive fibers carry pain 
signaling into the central nervous system (Krarup, 2003).  If this type of glutamate 
signaling could be blocked during opioid treatment for pain, the administered 
opioid may display greater analgesic efficacy.  With this in mind, researchers 
from our laboratory and others’ have focused their efforts on the blockade of a 
widely distributed, ionotropic glutamate receptor, the NMDA receptor, in 
combination with opioid agonist treatment.   
Preclinical research conducted on the antinociceptive efficacy of opioid 
agonist/NMDA antagonist combinations indicates that antinociception can be 
enhanced with these combinations.  Fischer et al. (2005) found that an NMDA 
antagonist enhanced the acute antinociceptive effect of morphine in the tail-flick 
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test of thermal nociception, an effect also seen with lower efficacy opioids 
(Fischer et al., 2006).  A large number of preclinical studies have found that 
NMDA antagonism can enhance opioid analgesia in mouse models of acute pain  
(Fischer et al., 2005; Fischer et al., 2006), in rat models of chronic pain  (Lomas 
et al., 2008; Henry et al., 2008), and in non-human primate studies of pain and 
analgesia (Allen & Dykstra, 2001).  Chen et al. (2005) reported an enhancement 
of morphine antinociception by the NMDA antagonist dextromethorphan, but an 
attenuation of acute codeine antinociception, suggesting an interaction between 
the two receptor systems.  An interaction between the two systems is further 
supported by the findings of Nemanni et al. (2004), in which NMDA antagonism 
enhanced low-dose morphine antinociception but attenuated high-dose morphine 
antinociception.  Furthermore, in addition to its effects on the acute 
antinociceptive effects of MOR agonist compounds, NMDA antagonism also 
prevents the development of tolerance to the antinociceptive effects of morphine 
(Allen & Dykstra, 2000; Kozela et al., 2003; Trujillo & Akil, 1991) in rodents and 
primates.  Moreover, some NMDA antagonists decrease physical dependence 
associated with chronic morphine exposure (Trujillo & Akil, 1991). 
Taken together, preclinical studies of NMDA antagonists in combination 
with morphine and other opioid compounds show promise for enhancing clinical 
analgesia; however, clinical studies reveal mixed results.  For example, whereas 
Bossard et al. (2002) found that the NMDA antagonist ketamine enhanced 
morphine analgesia, a similar study by Galer et al. (2005) with the NMDA 
antagonist dextromethorphan did not reveal a similar effect.  Additionally, clinical 
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reports of side effects such as nausea, dizziness, and fatigue limit the use of 
these combinations.  In much the same way that the gastrointestinal side effects 
of MOR agonists are due to the receptor’s prevalence in the gastrointestinal tract, 
the widespread anatomical distribution and functionality of the NMDA receptor 
may make its pharmacological targeting produce a range of side effects. 
Given the limitations of NMDA antagonist treatment, many preclinical 
researchers are studying the roles of other glutamate receptors in pain 
regulation.  The Group I family of the metabotropic class of glutamate receptors 
is particularly interesting in this respect.  The metabotropic glutamate receptor 
subtypes 1 (mGluR1) and 5 (mGluR5) are post-synaptic receptors which are 
highly expressed in areas of the pain processing system, most notably on 
peripheral afferent nociceptive fibers (Walker et al., 2001b; Young et al., 1997) 
and in the dorsal horn neurons of the spinal cord (Alvarez et al., 2000; Jia et al., 
1999; Pitcher et al., 2007).  Given the high expression of mGluR1 and mGluR5 in 
peripheral nociceptive fibers and in the dorsal horn, an area which receives 
nociceptive input from peripheral fibers and carries that input further into parts of 
the central nervous system densely populated with MORs, it is interesting to 
examine interactions between opioid analgesics and mGluR antagonists. 
The growing body of literature on Group I mGluR antagonist/µ-opioid 
combinations implicates the mGluR1 receptor in modulation of pain processing 
and opioid analgesia in acute pain states while the mGluR5 receptor has been 
implicated in modulation of pain processing and opioid analgesia in chronic and 
inflammatory pain states.  Research utilizing preclinical models of acute pain 
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(clinical pain states that typically result from a known, short-lived noxious input, 
such as post-surgical pain) has demonstrated that mGluR1 antagonism can 
produce antinociceptive effects when administered alone (Neugbauer et al., 
1999) and can enhance the acute antinociceptive effects of morphine and other 
µ-opioids (Fischer et al., 2008a; Fischer et al., 2008b).  Interestingly, the same 
mGluR1 antagonist (JNJ16259685) used in the Fischer et al. studies was also 
examined in a model of chronic pain and did not enhance morphine analgesia 
(Henry et al., 2008).  These data support the hypothesis that the mGluR1 site is 
an important modulator of acute pain processing and analgesia. 
Studies of chronic pain states (clinical pain states that typically result from 
sustained inflammatory input that can actually alter the functionality of the pain 
processing system), however, indicate that mGluR5 antagonists can enhance 
morphine’s analgesic effects.  Studies employing inflammatory models of chronic 
hyperalgesia and allodynia have shown enhancement of morphine 
antihyperalgesia by mGluR1/5 antagonists (Fisher & Coderre, 1996) and 
selective mGluR5 antagonists (Gabra et al., 2008; Kozela et al., 2003).  
Furthermore, some mGluR5 antagonists produce antihyperalgesic effects when 
administered alone in inflammatory models (Lee et al., 2006; Walker et al., 
2001a; Walker et al., 2001b) and inhibit the development of tolerance to the 
antinociceptive effects of morphine following chronic morphine exposure (Gabra 
et al., 2008; Kozela et al., 2003; Smith et al., 2004).  Furthermore, the mGluR5 
receptor has been shown to up-regulate in response to persistent inflammation 
(Dolan et al., 2003) and in response to post-surgical pain (Dolan et al., 2004). 
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While the literature seems to point to differential roles between mGluR1 
and mGluR5 in pain and analgesia modulation, there have been no published 
studies to date that have examined both mGluR1 and mGluR5 antagonists in 
both acute and inflammatory/chronic pain models within a single animal species.  
Differences across published studies include species studied (i.e., mouse vs. 
rat), type of pain modeled (i.e., acute vs. chronic), and mGluR subtype targeted 
(i.e., mGluR1 vs. mGluR5), which makes it difficult to reach conclusions 
regarding the roles of each receptor in pain and opioid modulation.  Furthermore, 
there are occasional reports in the literature of mGluR1 antagonism producing 
analgesic effects in chronic pain models.  For example, the mGluR1 antagonist 
CPCCOEt decreased nociceptive behaviors in rats with chronic constriction 
nerve injuries and Complete Freund’s Adjuvant pretreatment (Kumar et al., 
2010), and antisense oligonucleotide knockdown of mGluR1 resulted in 
attenuation of cold-, heat-, and mechanical-allodynia in neuropathic rats 
(Fundytus et al., 2001).  These cases cannot be ignored, but, again, without a full 
examination of both receptor types in both types of pain models within a single 
animal species, conclusions are difficult to reach.  Therefore, the present study 
was designed to examine the effects of selective mGluR1 antagonism and 
selective mGluR5 antagonism alone and in combination with µ-opioid analgesia 
in models of both acute pain and inflammatory/chronic pain in a single animal 
species. 
 
 
7 
Experimental Aims 
The present study examined µ-opioid analgesics in combination with the 
mGluR1 antagonist JNJ16259685 ([(3,4-dihydro-2H-pyrano[2,3-b]quinolin-7-yl)-
(cis-4-methoxycyclohexl)-methanone]) and the mGluR5 antagonist MPEP (2-
methyl-6-(phenyl-ethynyl) pyridine hydrochloride) in the rat in models of both 
acute and inflammatory pain.  The mGluR1 antagonist JNJ16259685 (JNJ) was 
chosen for its relatively high selectivity for the mGlu1 receptor (Lavreysen et al., 
2004).  The mGluR5 antagonist MPEP was likewise chosen for its mGlu5 
receptor selectivity (Gasparini et al., 1999) and for its widespread use as the 
prototypical mGluR5 antagonist. 
 
Experiment 1 
Experiment 1 examined the antinociceptive effects of the mGluR1 
antagonist JNJ16259685 and the mGluR5 antagonist MPEP alone and in 
combination with morphine in two rat models of acute pain.  The warm-water tail 
withdrawal assay and the hot plate assay were used to assess the 
antinociceptive effects of these drugs and their selected combinations.  Both of 
these tests have been used successfully in our laboratory (Fischer et al., 2008b) 
as well as in other studies (Lomas et al., 2008) of opioid analgesia in combination 
with glutamatergic antagonists. 
The warm-water tail withdrawal assay is a model of acute thermal pain in 
which an animal’s tail is placed in a heated water bath, and the latency to 
withdrawal the tail is measured.  The tail withdrawal response is a reflexive pain 
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behavior.  This reflexive test provides insight into the antinociceptive effects of 
drugs at a spinal level. 
The hot plate assay is a model of acute thermal pain in which an animal is 
placed on a hot plate analgesia meter, and the latency to perform a number of 
different escape behaviors is measured.  Traditionally, these behaviors include 
fluttering of the hind paw, licking of the hind paw, and jumping to escape the hot 
plate.  All of these behaviors require a locomotor component, thus, this is a test 
of a more integrated antinociceptive response, as compared to the tail withdrawal 
test.  While this does provide insight into the more integrated antinociceptive 
effects of drugs, it is important to remember that this is a pain assay which is 
subject to a drug’s locomotor-impairing effects. 
The mGluR1 antagonist JNJ16259685 and the mGluR5 antagonist MPEP 
were tested both alone and in combination with doses of morphine in both of 
these acute pain assays.  The purpose of testing the mGluR antagonists alone 
was three-fold:  1) to assess any antinociceptive effects that these drugs may 
have on their own, 2) to increase antagonist doses as high as needed to ensure 
they were functionally active, and 3) to assess the time course of those 
functionally active doses.   
 
Experiment 2 
Experiment 2 examined the antihyperalgesic effects of the mGluR1 
antagonist JNJ16259685 and the mGluR5 antagonist MPEP alone and in 
combination with morphine in an inflammation-based model of chronic pain.  The 
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capsaicin-induced hyperalgesic tail withdrawal assay was used to study these 
effects.  In this procedure, the inflammatory agent capsaicin, an extract of red 
peppers, is administered to the distal end of an animal’s tail and the latency to 
withdraw the tail from a previously non-noxious water bath is recorded.  One 
common problem of many chronic pain models is difficulty in controlling for the 
level of nociception induced by the administered inflammatory agent.  Barrett et 
al. (2002) found that localization of capsaicin-induced inflammation to the tail 
produced highly consistent levels of nociception under baseline conditions.  For 
this reason, and for the successful use of this assay in previous studies of 
morphine antihyperalgesia in combination with NMDA antagonism (Lomas et al., 
2008), this assay was selected to investigate the effects of µ-opioid/mGluR 
antagonist combinations in a chronic pain model. 
Selected doses of the mGluR1 antagonist JNJ16259685 and the mGluR5 
antagonist MPEP were tested both alone and in combination with varying doses 
of morphine.  In testing the mGluR antagonists alone, information about the 
antihyperalgesic effects of each antagonist when administered alone could be 
evaluated before combining selected doses with morphine. 
  
 
 
CHAPTER 2 
METHODS AND MATERIALS 
 
Animals 
Adult male Fischer344 rats 2-3 months of age were purchased from 
Charles River Laboratories (Raleigh, NC).  Upon arrival, rats were individually 
housed in standard Plexiglas cages with ad libitum food and water.  Rats were 
habituated to a colony room maintained on a 12-hour light/dark cycle, with lights 
on at 7:00 AM, for at least 1 week before testing.  Rats were handled and 
exposed to experimenter restraint on at least 3 separate occasions before the 
beginning of testing.  Rats were transported from the colony room to the testing 
environment each test day and habituated to the test room for at least 1 hour 
before testing on each occasion.  Both the handling and room habituation 
protocols were followed to minimize the effect of stress and novelty during all test 
sessions.  All experiments were performed in the light phase of the animals’ 
light/dark cycle, between the hours of 10:00 AM and 4:00 PM.  No animal was 
tested more than once per week.  All animals used in this study were cared for in 
accordance with a protocol approved by and the guidelines laid out by the 
Institutional Animal Care and Use Committee at the University of North Carolina 
at Chapel Hill.   
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Drugs 
Morphine sulfate and buprenorphine hydrochloride were provided by the 
National Institute on Drug Abuse (Bethesda, MD).  JNJ16259685 and MPEP 
were purchased from Tocris Biosciences (Ellisville, MO).  Isoflurane was 
purchased from Phoenix Pharmaceuticals (St. Joseph, MO).  Capsaicin was 
purchased from Sigma-Aldrich, Inc. (St. Louis, MO).  Morphine sulfate, 
buprenorphine hydrochloride, and MPEP were dissolved in a 0.9% phosphate-
buffered saline solution.  JNJ16259685 was dissolved in 45% (w/v) 2-
hydroxypropyl-β-cyclodextrin.   Capsaicin was dissolved in a solution of Tween 
80/95% ethanol/saline in a 1/1/8 ratio, which was further diluted with saline.  
Morphine sulfate, buprenorphine hydrochloride, and capsaicin were prepared in 
stock solutions and further diluted with saline for the preparation of selected 
doses.  Selected doses of JNJ16259685 and MPEP were prepared acutely.  
Morphine, buprenorphine, JNJ16259685 and MPEP were all administered i.p. at 
a volume of 0.1mL/100g.  Capsaicin was administered locally to the tail in a set 
volume of 0.1 mL.  Animals were exposed to isoflurane anesthesia in an 
inhalational chamber. 
 
Experiment 1 
Experiment 1 examined morphine antinociception in combination with 
selected doses of the mGluR antagonist JNJ16259685 or the mGluR5 antagonist 
MPEP.  Antinociception was assessed using the warm-water tail withdrawal 
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assay and the hot plate assay.  Animals were tested twice in each assay under 
baseline conditions to yield an average baseline latency measure for each 
animal.  Within each test session, animals were first tested in the tail withdrawal 
procedure and then in the hot plate procedure.  Originally, this test order was 
counter-balanced, but, pilot investigations indicated baseline response levels 
were inconsistent when rats were examined on the hot plate prior to the tail 
withdrawal procedure (data not shown).  Therefore, rats were examined first in 
the tail withdrawal procedure throughout the study.  A cumulative morphine 
dosing procedure was used to obtain each morphine dose-effect curve.  The 
selected mGluR antagonist dose was administered once prior to obtaining each 
cumulative dose-effect curve.  Injections were timed such that the mGluR 
antagonist was administered 30 min before initiating the morphine dose-effect 
curve, and each cumulative morphine dose was administered 15 min prior to 
each test point within the entire session.  Maximum latency values were set at 15 
sec in the tail withdrawal assay and at 40 sec in the hot plate assay to prevent 
tissue damage and to allow for the conversion of raw latency data to % 
antinociceptive effect data.  Maximum latency values also differed between tests 
due to baseline differences in latency values between the two assays, with 
baseline response latencies averaging 4 sec in the tail withdrawal procedure and 
10 sec in the hot plate procedure. 
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Warm-water Tail Withdrawal Assay 
Rats were removed from their home cages and lightly restrained while the 
distal 7 cm of the tail was placed into a 52°C water bath.  The tail withdrawal 
latency was recorded.  A cutoff limit of 15 sec was used to avoid tissue damage, 
at which point the animal was removed from testing, and a maximum latency of 
15 sec was recorded.   
 
Hot Plate Assay 
Immediately following testing in the warm-water tail withdrawal procedure, 
rats were placed on a hot plate analgesia meter set at 52°C.  Latency to lick the 
hind paw or perform an escape response was recorded.  A cutoff limit of 40 sec 
was used to prevent tissue damage, at which point the rat was removed from the 
hot plate and returned to the home cage, and a maximum latency of 40 sec was 
recorded. 
 
Experiment 2 
Experiment 2 examined morphine antihyperalgesia in combination with the 
mGluR1 antagonist JNJ16259685 or the mGluR5 antagonist MPEP.  A tail 
withdrawal procedure, with the introduction of inflammation to the tail, was used 
to model chronic pain states and assess antihyperalgesia.  Due to the 
administration of the inflammatory agent capsaicin, a cumulative morphine 
dosing procedure could not be used in this experiment.  A maximum latency 
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value of 15 sec was used in this assay to prevent tissue damage and to allow for 
the conversion of raw latency data to % antinociceptive effect data. 
 
Capsaicin-induced Hyperalgesic Tail Withdrawal Assay 
Prior to the induction of an inflammatory state, each animal was lightly 
restrained and the distal 7 cm of the tail was immersed in a 45°C water bath to 
ensure that each animal’s tail would remain immersed at this temperature up to 
the experimentally imposed maximum latency of 15 sec.  Any animal that failed 
to do so was removed from the experiment.  Hyperalgesia was induced by 
injecting 3.0 µg capsaicin 3.5 cm into the distal end of the tail, under isoflurane 
anesthesia using an inhalational drop-method.  Animals were placed into a 
chamber prepared with approximately 1.0 mL isoflurane and observed for 
sedation.  Animals were then removed and administered capsaicin locally to the 
tail and placed back in the home cage.  Rats recovered from the procedure within 
2-3 min.  After administration of capsaicin, tail-withdrawal latencies decreased 
from 15 sec to an average of 4 sec in response to the same 45°C water bath. 
Before initiating testing, a capsaicin baseline was assessed in each rat. 
During morphine dose-effect curve test sessions, rats were randomly assigned to 
receive varying doses of morphine either alone or in selected combinations with 
either JNJ or MPEP.  This administration preceded behavioral testing by 30 min.  
Capsaicin administration preceded testing by 15 min.   During behavioral testing, 
animals were lightly restrained, the distal 7cm of the tail was immersed, and the 
latency to withdraw the tail was recorded.  For all tests of antihyperalgesia, a 
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15 sec cutoff latency was used as this indicated a maximal antihyperalgesic 
effect (i.e., withdrawal latencies returned to pre-inflammation baseline levels).   
 Selected doses of each mGluR antagonist were also tested alone in this 
assay.  Such tests followed the same time course as described above. 
 
Data Analysis 
For all tests of opioid antinociception and antihyperalgesia, raw latency 
scores were converted to % maximum possible effect scores using the following 
equation: 
% MPE = [(observed – baseline) / (maximum – baseline)] × 100. 
When possible, the %MPE scores from dose-effect curves examining 
antinociception and antihyperalgesia were used to mathematically derive the 
dose of the opioid required to produce a 50% analgesic effect (ED50) either 
alone or in combination with an mGluR antagonist.  Calculation of the ED50 
value required the following:  1) an ascending limb of the dose effect curve 
comprised of at least 3 points and, 2) that the lowest mean %MPE within this 
limb was 20% or lower, and the highest mean %MPE was 80% or higher.   
When the ED50 value could be calculated, relative potency estimates 
between each opioid given alone and in combination with the mGluR antagonists 
were also determined.  For this analysis, dose ratios were calculated by 
comparison of the slopes of two linear regression lines representing two dose-
effect curves and the distance between those two lines, a method described by 
Tallarida and Murray (1987).  Differences in the relative potency of each opioid 
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alone and in combination were considered to be significant if the 95% confidence 
interval did not overlap 1.0 or below. 
When calculation of the ED50 value was not possible (i.e., the dose-effect 
curve did not meet requirements noted above), comparisons were made between 
the opioid dose-effect curve and the opioid/mGluR antagonist combination dose-
effect curves by conducting a two-factor analysis of variance (ANOVA).  The 
opioid and the mGluR antagonist administered were set as the two factors with 
specific doses of each as the levels of each factor.  In post-hoc analyses, the 
mean analgesic effects of each drug combination were compared to determine 
specific opioid/mGluR antagonist dose combinations that were significantly 
different from the opioid administered alone. 
For tests of mGluR antagonist functional activity and time course in each 
antinociceptive and antihyperalgesic test, raw latency scores following drug 
administration were compared to baseline latency scores by conducting a 
repeated measures ANOVA with dose as the between-groups factor and time 
point as the repeated measures factor.  The Fisher protected least significant 
differences (PLSD) test was used in post hoc analyses.   
  
 
 
 
CHAPTER 3 
RESULTS 
 
Experiment 1 
Experiment 1 examined the antinociceptive effects of the mGluR1 
antagonist JNJ16259685 and the mGluR5 antagonist MPEP both alone and in 
combination with morphine in two models of acute pain: the warm-water tail 
withdrawal procedure and the hot plate procedure.  Figure 1 presents the effects 
of JNJ on % maximum possible effect in the warm-water tail withdrawal 
procedure.  The bottom portion of Fig 1 (1d – 1f) shows the effects of selected 
doses of JNJ alone, determined at 15, 30, 45, and 60 min post-injection.  Neither 
1.0 nor 3.0 mg/kg JNJ significantly increased %MPE at these time points; 
however, a dose of 5.6 mg/kg JNJ produced an average MPE of approximately 
25% at 30, 45, and 60 min post-injection.  The top portion of Fig 1 (1a – 1c) 
presents the effects of JNJ in combination with morphine.  The 3.0 mg/kg dose of 
JNJ and the 5.6 mg/kg dose of JNJ shifted the morphine dose-effect curve 
leftward, 1.7-fold and 1.9-fold, respectively. 
 Figure 2 presents the effects of JNJ in the hot plate procedure, with the 
effects of JNJ alone presented in the bottom portion (2d – 2f).  Both the 1.0 
mg/kg and the 3.0 mg/kg dose of JNJ increased %MPE in the hot plate 
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procedure, but these effects were brief and generally only occurred during the 
first 15-30 min after administration.  The 1.0 mg/kg dose of JNJ increased %MPE 
by 40% at 15 min post injection.  At 30 min post-injection, the 3.0 mg/kg dose of 
JNJ increased %MPE by 22%.  The top portion of Fig 2 (2a – 2c) presents the 
effects of JNJ in combination with morphine in the hot plate procedure.  The 1.0 
mg/kg dose of JNJ produced a significant 3.5-fold shift to the left in the morphine 
dose-effect curve.  The 3.0 mg/kg dose of JNJ produced a significant 2.6-fold 
shift to the left in the morphine dose-effect curve. 
Figure 3 presents the effects of MPEP on % maximum possible effect in 
the warm-water tail withdrawal procedure.  The bottom portion of Fig 3 (3d – 3f) 
shows the effects of selected doses of MPEP alone, determined at 15, 30, 45, 
and 60 min post-injection.  Neither 3.0 mg/kg nor 10.0 mg/kg MPEP significantly 
increased %MPE at these time points; however, a dose of 30.0 mg/kg MPEP 
produced an MPE of 29% at 30 min post-injection and an MPE of 34% at 45 min 
post-injection.  The top portion of Fig 3 (3a – 3c) presents the effects of MPEP in 
combination with morphine.  The 30.0 mg/kg dose of MPEP shifted the morphine 
dose-effect curve leftward, 2.3-fold. 
 Figure 4 presents the effects of MPEP in the hot plate procedure, with the 
effects of MPEP alone presented in the bottom portion (4d – 4f).  Neither the 3.0 
mg/kg nor the 10.0 mg/kg dose of MPEP significantly increased %MPE in the hot 
plate procedure.  The 30.0 mg/kg dose of MPEP increased %MPE by 25% at 15 
min post-injection and by 21% at 30 min post-injection.  The top portion of Fig 4 
(4a – 4c) presents the effects of MPEP in combination with morphine in the hot 
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plate procedure.  The 30.0 mg/kg dose of MPEP produced a significant 6.2-fold 
shift to the left in the morphine dose-effect curve. 
 
Experiment 2 
Experiment 2 examined the antihyperalgesic effects of JNJ and MPEP 
both alone and in combination with morphine in a model of inflammatory pain: the 
capsaicin-induced hyperalgesic tail withdrawal procedure.  Figure 5 presents the 
effects of JNJ in the capsaicin tail withdrawal procedure.  JNJ did not significantly 
increase %MPE when given alone at any of the doses tested, nor did it produce 
consistent alterations in the effects of morphine, resulting in no shift in the 
morphine dose-effect curve.  
Figure 6 presents the effects of MPEP in the capsaicin-induced 
hyperalgesic tail withdrawal procedure.  Neither the 1.0 mg/kg dose nor the 3.0 
mg/kg dose of MPEP significantly increased %MPE when given alone; however, 
the 10.0 mg/kg dose of MPEP increased %MPE by 62%.  When this dose of 
MPEP was combined with morphine, it produced a bi-phasic effect on the 
morphine dose-effect curve, increasing %MPE of low morphine doses and 
decreasing %MPE of high morphine doses.  A two-factor ANOVA revealed a 
significant main effect of morphine (F=28.9, p<0.001) and a significant interaction 
between morphine and MPEP (F=2.9, p<0.05) but no significant main effect of 
MPEP.  Post hoc analyses revealed that the 10.0 mg/kg dose of MPEP 
significantly attenuated the effects produced by high doses of morphine and 
20 
produced a strong trend (p<0.1) toward enhancement of the effects produced by 
a low dose of morphine. 
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Figure 1.  Effects of the mGluR1 antagonist JNJ16259685 on morphine-
induced antinociception in the tail withdrawal assay.  
 
Panels 1a-1c:  Data are presented as mean %MPE ± S.E.M. on the ordinate as a 
function of morphine dose on the abscissa.  An asterisk (*) represents a 
significant shift to the left of the morphine dose-effect curve by the given JNJ 
dose. 
 
Panels 1d-1f:  Effects of JNJ when given alone in the tail withdrawal assay.  Data 
are presented as mean %MPE ± S.E.M. on the ordinate as a function of time 
point following injection on the abscissa.  Note that the effects of JNJ in 
combination with morphine (panels 1a-1c) align vertically between panels with 
the effects of JNJ when given alone at the same time point post injection (panels 
1d-1f). 
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Figure 2.  Effects of the mGluR1 antagonist JNJ16259685 on morphine-
induced antinociception in the hot plate assay.  
Panels 2a-2c:  Data are presented as mean %MPE ± S.E.M. on the ordinate as a 
function of morphine dose on the abscissa.  An asterisk (*) represents a 
significant shift to the left of the morphine dose-effect curve by the given JNJ 
dose. 
 
Panels 2d-2f:  Effects of JNJ when given alone in the hot plate assay.  Data are 
presented as mean %MPE ± S.E.M. on the ordinate as a function of time point 
following injection on the abscissa.  Note that the effects of JNJ in combination 
with morphine (panels 2a-2c) align vertically between panels with the effects of 
JNJ when given alone at the same time point post injection (panels 2d-2f). 
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Figure 3.  Effects of the mGluR5 antagonist MPEP on morphine-induced 
antinociception in the tail withdrawal assay.  
Panels 3a-3c:  Data are presented as mean %MPE ± S.E.M. on the ordinate as a 
function of morphine dose on the abscissa.  An asterisk (*) represents a 
significant shift to the left of the morphine dose-effect curve by the given MPEP 
dose. 
 
Panels 3d-3f:  Effects of MPEP when given alone in the tail withdrawal assay.  
Data are presented as mean %MPE ± S.E.M. on the ordinate as a function of 
time point following injection on the abscissa.  Note that the effects of MPEP in 
combination with morphine (panels 3a-3c) align vertically between panels with 
the effects of MPEP when given alone at the same time point post injection 
(panels 3d-3f). 
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Figure 4.  Effects of the mGluR5 antagonist MPEP on morphine-induced 
antinociception in the hot plate assay.  
 
Panels 4a-4c:  Data are presented as mean %MPE ± S.E.M. on the ordinate as a 
function of morphine dose on the abscissa.  An asterisk (*) represents a 
significant shift to the left of the morphine dose-effect curve by the given MPEP 
dose. 
 
Panels 4d-4f:  Effects of MPEP when given alone in the hot plate assay.  Data 
are presented as mean %MPE ± S.E.M. on the ordinate as a function of time 
point following injection on the abscissa.  Note that the effects of MPEP in 
combination with morphine (panels 4a-4c) align vertically between panels with 
the effects of MPEP when given alone at the same time point post injection 
(panels 4d-4f). 
  
25 
 
0
20
40
60
80
100
Morphine
+ JNJ 1.0 mg/kg
1.0 3.0 10.00.0
0
20
40
60
80
100 Morphine
+ JNJ 3.0 mg/kg
0.3 1.0 3.0 10.00.0
0
20
40
60
80
100 Morphine
+ JNJ 5.6 mg/kg
3.01.0 10.00.0
JNJ + Morphine: Capsaicin Tail  Withdrawal
(a) (b) (c)
%
 
M
PE
Morphine (mg/kg)
 
 
 
Figure 5.  Effects of the mGluR1 antagonist JNJ16259685 on morphine-
induced antihyperalgesia in the capsaicin-induced hyperalgesic tail 
withdrawal assay.    
 
Data are presented as mean %MPE ± S.E.M. on the ordinate as a function 
of morphine dose on the abscissa.  Analysis of ED50 and potency ratio 
values revealed that no dose of JNJ tested produced a significant shift in the 
morphine dose-effect curve. 
  
26 
 
 
0
20
40
60
80
100 Morphine
+ MPEP 1.0 mg/kg
1.0 3.0 10.00.0
0
20
40
60
80
100 Morphine
+ MPEP 3.0 mg/kg
1.0 3.0 10.00.0
0
20
40
60
80
100 Morphine
+ MPEP 10.0 mg/kg
0.3 1.0 3.0 10.00.0
MPEP + Morphine: Capsaicin Tail Withdrawal
(a) (b) (c)
*
*
#
Morphine (mg/kg)
%
 
M
PE
 
 
 
Figure 6.  Effects of the mGluR5 antagonist MPEP on morphine-
induced antihyperalgesia in the capsaicin-induced hyperalgesic tail 
withdrawal assay.    
 
Data are presented as mean %MPE ± S.E.M. on the ordinate as a function 
of morphine dose on the abscissa.  An asterisk (*) represents a significant 
difference (p<0.05) between the antihyperalgesic effect produced by a given 
dose of morphine alone and in combination with MPEP.  A pound (#) 
represents a trend (p<0.1) toward a difference in the antihyperalgesic effect 
produced by a give dose of morphine alone and in combination with MPEP. 
  
 
 
 
 
 
CHAPTER 4 
 
DISCUSSION 
 
 
 
The present study examined the effects of the mGluR1 antagonist 
JNJ16259685 and the mGluR5 antagonist MPEP in rat models of acute and 
inflammatory pain.  Experiment 1 examined the antinociceptive properties of JNJ 
and MPEP in the warm-water tail withdrawal procedure and the hot plate 
procedure.  In both procedures, selective doses of JNJ and MPEP produced 
antinociception when administered alone and enhanced morphine-induced 
antinociception. 
A 5.6 mg/kg dose of the mGluR1 antagonist JNJ produced significant 
antinociception when administered alone and shifted the morphine dose-effect 
curve leftward 1.9-fold in the warm-water tail withdrawal procedure.  A slightly 
lower dose (3.0 mg/kg) did not produce significant antinociception alone in the 
tail withdrawal procedure but did produce a 1.7-fold shift to the left in the 
morphine dose-effect curve.  In the hot plate procedure, a 3.0 mg/kg dose of JNJ 
produced significant antinociception when administered alone and produced a 
significant 2.6-fold shift to the left in the morphine dose-effect curve while a 
slightly lower dose (1.0 mg/kg) did not produce significant antinociception alone 
at a relevant time point but did significantly shift the morphine dose-effect curve 
leftward, 3.5-fold.  These data are in agreement with a number of studies 
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reporting the antinociceptive efficacy of mGluR1 antagonists (Fischer et al., 
2001a; Fischer et al., 2001b; Neugbauer et al., 1999). 
It is interesting to note that JNJ displayed antinociceptive properties 
differentially between the two acute pain assays.  That is, JNJ produced 
significant antinociception and significant leftward shifts in the morphine dose-
effect curves in both assays, however, the magnitude of the shift was smaller in 
the tail withdrawal test (1.7 - 1.9-fold) than in the hot plate test (2.6 - 3.2-fold).  
Furthermore, these results were produced by different doses of JNJ; the 3.0 
mg/kg and 5.6 mg/kg doses significantly enhanced morphine antinociception in 
the tail withdrawal test while the 1.0 mg/kg and 3.0 mg/kg doses did so in the hot 
plate test.  These differences are not entirely surprising as these two tests are 
differential in nature.  The tail withdrawal test requires a reflexive response while 
the hot plate test requires a more integrated pain response.  The differences in 
the results of JNJ between these two procedures point to the importance of the 
pain assay used when evaluating the analgesic efficacy of a compound. 
Experiment 1 also showed that a 30.0 mg/kg dose of the mGluR5 
antagonist MPEP produced significant antinociceptive effects alone.  Moreover, 
this dose of MPEP significantly shifted the morphine-dose effect curve to the left.  
This effect contrasts with the findings of Fischer et al. (2008a; 2008b) which 
indicated that MPEP did not enhance µ-opioid-induced antinociception in the tail-
flick and hot plate assays.  However, there are important differences between the 
present results and those reported by Fischer et al.  First of all, the present study 
used a rat model while the Fischer et al. studies used mice.  Furthermore, the 
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present study used the warm-water tail withdrawal procedure while the former 
Fischer et al. (2008a) study used the tail-flick procedure.   
It is also important to note that a 30.0 mg/kg i.p. dose of MPEP is a 
considered to be a relatively high dose which may not be fully selective to 
mGluR5; Montana et al. (2009) reported that the same dose of MPEP also given 
i.p. in mGluR5 knockout mice produced significant analgesia in the formalin test, 
suggesting that MPEP is probably active at another site at this dose, at least in 
mGluR5 knockout mice.  Though MPEP is the prototypical mGluR5 antagonist, a 
number of studies have cited its inferiority in selectivity for mGluR5 as compared 
to newer antagonists such as 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine 
(MTEP) and [N-(3-chlorophenyl)-N'-(4,5-dihydro-1-methyl-4-oxo-1H-imidazole-2-
yl)urea] (fenobam) (Lea & Faden, 2006; Montana et al., 2009).  Therefore, 
although a 30.0 mg/kg dose of MPEP produced significant antinociception and 
enhancement of morphine antinociception in two rat models of acute pain, it is 
likely that these effects are not mediated through the mGluR5 system. 
Experiment 2 examined the antihyperalgesic properties of JNJ16259685 
and MPEP in a rat model of inflammatory pain: the capsaicin-induced 
hyperalgesic tail withdrawal procedure.  In this experiment, JNJ neither produced 
antihyperalgesic effects when administered alone nor enhanced morphine-
induced antihyperalgesia.  These findings are in agreement with a number of 
other studies which have shown that mGluR1 antagonists are not active in 
inflammatory pain models (Gabra et al., 2008; Lee et al., 2006; Walker et al., 
2001a). 
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In contrast, a 10.0 mg/kg dose of the mGluR5 antagonist MPEP produced 
significant antihyperalgesia when given alone in the capsaicin-induced 
hyperalgesic tail withdrawal procedure.  This effect is in agreement with other 
studies in which selected mGluR5 antagonists, when administered alone, 
produced antihyperalgesic effects in inflammatory models (Lee et al., 2006; 
Walker et al., 2001a; Walker et al., 2001b). Interestingly, the 10.0 mg/kg dose of 
MPEP did not enhance morphine-induced antihyperalgesia.  Instead, it appeared 
to attenuate the analgesic effects of high doses of morphine.  Though this result 
was unexpected, it is not completely unprecedented.  Popik et al. (2000) reported 
a trend toward attenuation in morphine antinociception in the tail flick assay in 
mice by memantine and MRZ 2/579, antagonists of the NMDA ionotropic 
glutamate recepotor.  Furthermore, Nemmani et al. (2004) reported that another 
NMDA antagonist, dextromethorphan, enhanced low-dose morphine 
antinociception but attenuated high-dose morphine antinociception in the warm-
water tail withdrawal procedure in mice.  Furthermore, the bi-phasic pattern 
reported in the Nemmani et al. study was also observed in the present study with 
the 10.0 mg/kg dose of MPEP producing a slight enhancement of the 
antihyperalgesic effects of low doses of morphine.  This enhancement may be 
difficult to interpret, however, given that 10.0 mg/kg MPEP produced 
antihyperalgesic effects when administered alone. 
 Interpreting the results of combinations of morphine and MPEP in the 
capsaicin procedure may prove difficult.  Given the bi-phasic pattern of MPEP’s 
effects on morphine antihyperalgesia, an interaction between the mGluR5 and 
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MOR receptor systems seems likely.  MPEP has been shown to decrease MOR 
phosphorylation, internalization, and desensitization in HEK293 cells co-
expressing mGluR5 and MOR (Schröder et al., 2009).  These processes may 
alter the availability of MOR to its ligands, an effect which may alter the analgesic 
efficacy of a given dose of a µ-opioid.  Receptor occupancy theory states that the 
pharmacologic response of a drug is proportional to the fraction of the target 
receptor population occupied by the drug at a given concentration (Ross & 
Kenakin, 2001). In accordance with this theory, if the number of MORs available 
to morphine is altered by MPEP, then the number of MORs occupied by 
morphine is likewise altered, thereby altering the behavioral response.  It is 
possible that under the inflammatory conditions and selected drug doses of the 
present study, 10.0 mg/kg MPEP may have decreased opiate receptor 
availability, thereby attenuating the antihyperalgesic effects of high doses of 
morphine.   
Further complicating the interpretation of the combination effects of MPEP 
and morphine in the capsaicin procedure is the fact that MPEP does display 
some non-selective activity at other glutamate receptors, most notably mGluR1 
and the NMDA receptor (Lea & Faden, 2006).  While MPEP and the more 
recently developed MTEP exhibit equal off-site effect for mGluR1, MPEP 
displays significantly more off-site activity at the NMDA receptor (Cosford et al., 
2003).  It is a possibility that 10.0 mg/kg MPEP, under our inflammatory model, 
may have produced some of its effects through activity at the NMDA receptor.  
The attenuation of morphine analgesia by this dose of MPEP would then agree 
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with the attenuation of morphine analgesia seen by other researchers with 
selected NMDA antagonists in other pain models (Popik et al., 2000; Nemmani et 
al., 2004).  Lastly, post-synaptic mGluR1 and mGluR5 activity has been shown to 
increase NMDA-mediated responses (Cerne & Randic, 1992; Kelso et al., 1992; 
Skeberdis et al., 2001), another possible explanation for the unpredicted results 
of MPEP administration. 
The behavioral results of the present study of Group I mGluR antagonists 
in acute and inflammatory pain modulation are further supported by a number of 
physiological studies examining the distribution and functionality of mGluR1 and 
mGluR5 within the nervous system (Dolan et al., 2003; Dolan et al., 2004; Pitcher 
et al., 2007; Walker et al., 2001b).  Functionally, mGluR5 has been shown to be 
upregulated in response to persistent inflammation (Dolan et al., 2003) and in 
response to post-surgical pain (Dolan et al., 2004) in sheep.  In contrast, mGluR1 
expression levels were unaltered under these conditions.  Walker et al. (2001b) 
found that mGluR5 receptors expressed on peripheral nociceptors are important 
mediators of inflammatory hyperalgesia.  Furthermore, Pitcher et al. (2007) 
examined the intracellular expression patterns of mGluR1 and mGluR5 in 
response to different pain states and found that only after induction of 
inflammation, was the mGluR5 receptor trafficked to the plasma membrane, 
where it is more readily involved in neurotransmission.  All the above studies 
provide demonstrations of inflammation altering mGluR5 levels but not those of 
mGluR1.  These findings provide support for the results of the present study in 
which the mGluR1 antagonist JNJ16259685 was not implicated in the 
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inflammatory capsaicin procedure.  Furthermore, these findings support the 
antihyperalgesia produced by a 10.0 mg/kg dose of the mGluR5 antagonist 
MPEP in the capsaicin procedure. 
Future studies examining the effects of Group I mGluR compounds on µ-
opioid analgesia might consider a number of other factors.  For example, sex is 
an important determinant in the efficacy of NMDA antagonists to alter µ-opioid 
analgesia (Lomas et al., 2008; Nemmani et al., 2004).  It is not yet clear if this 
trend also occurs with Group I mGluR anatagonism.  Expanding the number of 
inflammatory/chronic pain models would also be of interest.  There are 
indications that capsaicin administration produces both thermal and mechanical 
primary hyperalgesia, sensitization of peripheral nociceptive receptors and fibers; 
however there are also indications that capsaicin administration produces only 
mechanical secondary hyperalgesia, sensitization of the nociceptive neurons of 
the central nervous system (Willis, 2009).  The present study examined only 
thermal pain in response to capsaicin administration, meaning it is possible only 
primary hyperalgesia was examined.  It would be interesting to also examine 
either mechanical hyperalgesia in response to capsaicin or another more 
integrated inflammatory model such as Complete Freund’s Adjuvant to further 
examine the role of the mGluR system in secondary hyperalgesia, or central 
sensitization.  Additionally, the side effect profile (a large impediment in the 
clinical utility of NMDA antagonist treatments for pain) of Group I mGluR 
compounds has not been fully characterized.  While some reports indicate that 
newer mGluR compounds have a more limited side effect profile (Montana et al., 
34 
 
2009), impairments by mGluR5 antagonists in locomotor activity, rotarod 
performance and decreases in body temperature have been reported, as well as 
impairments by both mGluR5 antagonists and mGluR1 antagonists in operant 
responding for food (Varty et al., 2005). 
While the current study examined only Group I mGluR compounds, the 
prospect of manipulating the Group II mGluR receptors is increasingly promising 
in the treatment of pain.  The Group II family includes the mGluR2 and mGluR3 
pre-synaptic autoreceptors.  These receptors maintain optimal levels of 
glutamate neurotransmission through negative feedback mechanisms 
(Shigemoto & Mizuno, 2000; Cartmell & Schoepp, 2000).  Agonists of these 
receptors, therefore, produce decreases in glutamate activity similar to that of 
mGluR1 and mGluR 5 antagonists but without direct antagonism. 
A great number of studies examining mGluR2 and mGluR3 agonists in 
different pain models indicate that the use of mGluR2/3 agonists may be 
promising in the management of chronic and inflammatory pain.  The results of 
mGlu2/3 activation in preclinical acute pain models are mixed. For example, 
Varney & Gereau (2002) point to some involvement of Group II receptors in 
acute pain while Simmons et al., (2002) found that mGluR2/3 agonists were only 
efficacious in chronic pain models, not acute pain models.  However, the 
literature is remarkably consistent in the evaluation of mGluR2 and mGluR3 
activation in inflammatory and persistent pain states.  Group II mGluR activation 
has been shown to decrease peripheral sensitization in inflammatory states (Du 
et al., 2008), display analgesic efficacy in response to both acute and repeated 
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dosing in both persistent and inflammatory pain models (Jones et al., 2005), and 
to regulate inflammatory receptor function (i.e., the TRPV1 receptor) (Carlton et 
al., 2009).  In addition Dolan et al. found that mGluR3 expression is upregulated 
following persistent inflammation (2003) and post-surgical pain (2004).   
There is much less information concerning the combination of mGluR2/3 
compounds with opioid analgesics in the literature.  Popik et al. (2000) reported 
that mGlu2/3 agonists did attenuate the development of analgesic tolerance to 
morphine, but little has been done to examine the acute effects of mGluR2/3 
activation on morphine antinociception or antihyperalgesia.  This presents an 
interesting opportunity to extend the methodology of the present work to mGluR2 
and mGluR3 agonists in order to review such effects. 
The present study compliments and contributes to a body of literature 
discriminating between the roles of mGluR1 and mGluR5 in the modulation of 
pain and µ-opioid-induced analgesia between different pain states.  The mGluR1 
antagonist JNJ16259685 dose-dependently enhanced morphine-induced 
antinociception in both the warm-water tail withdrawal and hot plate procedures, 
but did not alter morphine’s effects in the capsaicin-induced hyperalgesic tail 
withdrawal procedure.  The mGluR5 anatonist MPEP did not alter morphine’s 
effects in the warm-water tail withdrawal procedure nor in the hot plate 
procedure, except at a very high dose which is likely not selective for mGluR5 
systems.  A slightly lower dose of MPEP produced significant antihyperalgesic 
effects in the capsaicin-induced hyperalgesic tail withdrawal procedure, but the 
same dose attenuated high-dose morphine antihyperalgesia.  Again, it is possible 
36 
 
that these results were not related solely to mGluR5 mechanisms.  The present 
data are in line with the hypothesis that the mGluR1 receptor is an important 
modulator of acute pain, but these data provide limited support for the 
suggestions that the mGluR5 receptor is an important modulator of inflammatory 
pain. 
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Appendix A.  Effects of the mGluR1 antagonist JNJ16259685 in the warm-
water tail withdrawal and hot plate assays.  Data are presented as mean 
latency ± S.E.M. on the ordinate as a function of time point following injection on 
the abscissa.  An asterisk (*) represents a significant increase from baseline. 
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Appendix B.  Effects of the mGluR5 antagonist MPEP in the warm-water tail 
withdrawal and hot plate assays.  Data are presented as mean latency ± 
S.E.M. on the ordinate as a function of time point following injection on the 
abscissa.  An asterisk (*) represents a significant increase from baseline. 
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Appendix C.  Effects of the mGluR1 antagonist JNJ16259685 and the 
mGluR5 antagonist MPEP in the capsaicin-induced hyperalgesic tail 
withdrawal assay.  Left panel, JNJ16259685; right panel, MPEP.  Data are 
presented as mean latency ± S.E.M. on the ordinate as a function of the dose of 
the antagonist administered on the abscissa.  An asterisk (*) represents a 
significant increase from baseline. 
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